Skip to main content
SpringerLink
Log in

Treatment of Lymphoma with 131I-Chimeric Monoclonal Antibodies

  • Chapter
  • First Online:
Therapeutic Nuclear Medicine

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 2634 Accesses

Abstract

Radioimmunotherapy is a safe, effective treatment of low grade lymphoma and increases overall survival, whilst preserving quality of life. Efficacy is comparable with that of standard rituximab chemotherapy regimens and 131I-rituximab radioimmunotherapy is associated with less toxicity. Radioiodinated chimeric anti-CD 20 monoclonal antibody offers practical, cost-effective radioimmunotherapy for routine clinical applications where regulatory or cost constraints limit the availability of proprietary radiolabelled murine anti-CD 20 monoclonal antibodies. 131I-rituximab has, in addition, the potential for safe, effective, repeated radioimmunotherapy upon relapse of non-Hodgkin lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Anderson DR, Grillo-López A, Varns C et al (1997) Targeting cytotoxic immunotherapy: targeted anticancer therapy using rituximab, a chimeric anti CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin’s B-cell lymphoma. Biochem Soc Trans 25:705–708

    CAS  PubMed  Google Scholar 

  • Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) (2004) Discharge of patients undergoing treatment of radioactive substances, radiation protection series no. 4

    Google Scholar 

  • Behr TM, Griesinger F, Riggert J et al (2002) High-dose myeloablative radioimmunotherapy of mantle cell non-hodgkin lymphoma with the iodine-131 labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Cancer Cytopathol CA 94(S4):1363–1372

    Google Scholar 

  • Bienert M, Reisinger I, Srock S et al (2005) Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin’s lymphoma: initial experience. Eur J Nucl Med Mol Imaging 32:1225–1233

    Article  CAS  PubMed  Google Scholar 

  • Bishton MJ, Leahy MF, Hicks RJ et al (2008) Repeat treatment with iodine-131 rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma who had previously responded to iodine-131 rituximab. Ann Oncol 19:1629–1633

    Article  CAS  PubMed  Google Scholar 

  • Boucek JA, Turner JH (2005) Validation of prospective whole body bone marrow dosimetry by SPECT/CT multimodality imaging in 131I-anti CD 20 rituximab radioimmunotherapy of non-Hodgkins lymphoma. Eur J Nucl Med Mol Imaging 32(4):458–469

    Article  CAS  PubMed  Google Scholar 

  • Dancey G, Violet J, Malaroda A et al (2009) A phase I clinical trial of CHT-25 a 131I-labeled chimeric anti-CD25antibody showing efficacy in patients with refractory lymphoma. Clin Cancer Res 15(24):7701–7710

    Article  CAS  PubMed  Google Scholar 

  • Fernandez HF, Escalon MP, Pereira D et al (2007) Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant 40(6):505–513

    Article  CAS  PubMed  Google Scholar 

  • Forrer F, Chen J, Fani M et al (2009) In vitro characterization of 177Lu radiolabelled chimeric anti-CD 20 monoclonal antibody and a preliminary dosimetry study. Eur J Nucl Med Mol Imaging 36:1443–1452

    Article  CAS  PubMed  Google Scholar 

  • Kruger PC et al (2012) Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma. Cancer Biother Radiopharm (in press)

    Google Scholar 

  • Grillo-López (2003) Rituximab (Rituxan®/MabThera®): the first decade (1993–2003). Expert Rev Anticancer Thera 3(6):767–779

    Google Scholar 

  • Hagberg H, Gisselbrecht C (2006) Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 17 (Suppl 4):iv31–iv32

    Google Scholar 

  • Horning SJ (1993) Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol (5 Suppl 5):75–88

    Google Scholar 

  • Hunter WM, Greenwood FC (1962) Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 194:495–496

    Article  CAS  PubMed  Google Scholar 

  • Illidge TM, Bayne M, Brown NS et al (2009) Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 113(7):1412–1421

    Article  CAS  PubMed  Google Scholar 

  • International Commission on Radiological Protection (ICRP) (2004) Release of patients after therapy with unsealed radionuclides ICRP publication 94

    Google Scholar 

  • Johnson PW, Rohatiner AZ, Whelan JS et al (1995) Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 13(1):140–147

    CAS  PubMed  Google Scholar 

  • Kaminski MS, Estes J, Zasadny KR et al (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96(4):1259–1266

    CAS  PubMed  Google Scholar 

  • Kaminski MS, Tuck M, Estes J et al (2005) 131I-tositumomab therapy as initial treatment for follicular treatment. N Engl J Med 352:441–449

    Article  CAS  PubMed  Google Scholar 

  • Kang HJ, Park YH, Cheon GJ et al. (2006) Radioimmunotherapy in refractory B-cell non-Hogkin’s lymphoma with I-131-labeled chimeric anti-CD20 C2B8 (I-131 rituximab): preliminary results. J Nucl Med Meeting Abstracts 47:484

    Google Scholar 

  • Kapadia NS, Engles J, Wahl RL (2008) In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. J Nucl Med 49:674–678

    Article  CAS  PubMed  Google Scholar 

  • Leahy MF, Turner JH (2011) Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10 year single institution experience in 142 consecutive patients. Blood 117(1):45–52

    Article  CAS  PubMed  Google Scholar 

  • Leahy MF, Seymour JF, Hicks RJ et al (2006) Multicenter phase 11 clinical study of Iodine-131 rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol 24:4418–4425

    Article  CAS  PubMed  Google Scholar 

  • Marcus R, Imrie K, Solal-Celigny P (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26(28):4579–4586

    Article  CAS  PubMed  Google Scholar 

  • Markwell MAK (1982) A new solid-state reagent to iodinate proteins: conditions for the efficient labelling of antiserum. Annal Biochem 125:427–432

    Article  CAS  Google Scholar 

  • McLauglin P, Grillo-Lopez AJ, Link BJ et al (1998) Rituximab chimeric anti-CD 20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833

    Google Scholar 

  • Reff ME, Carner K, Chambers KS et al (1994) Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD 20 Blood 83(2):435–445

    Google Scholar 

  • Scheidhauer K, Wolf I, Baumgartl HJ et al (2002) Biodistribution and kinetics of (131) I-labelled anti-CD 20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 29:1276–1282

    Article  CAS  PubMed  Google Scholar 

  • Skvortsova I, Skvortsov S, Popper BA et al (2006) Rituximab enhances radiation-triggered apoptosis in non-Hodgkin’s lymphoma cells via caspase-dependent and-independent mechanism. J Radiat Res 47:183–196

    CAS  PubMed  Google Scholar 

  • Spencer A, Prince HM, DeAngelo DJ et al (2007) Phase IA/II study or oral LBH589, a novel deacetylase inhibitor (ACi) administered on 2 schedules in patients with advanced hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 110:907

    Google Scholar 

  • Torres-Garcia E, Ferro-Flores G, Arteaga de Murphy C et al (2008) Bokinetics and dosimetry of 188Re-anti-CD 20 in patients with non-Hodgkin’s lymphoma: preliminary experience. Arch Med Res 39:100–109

    Article  CAS  PubMed  Google Scholar 

  • Tran L, Baars JW, Maessen HJ et al (2009) A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy. Cancer Bioth Radiopharm 24:103–110

    Google Scholar 

  • Turner JH (2009) Defining pharmacokinetics for individual patient dosimetry in routine radiopeptide and radioimmunotherapy of cancer: Australian experience. Curr Pharm Des 15:966–982

    Article  CAS  PubMed  Google Scholar 

  • Turner JH, Martindale AA, Boucek J et al (2003) 131I-anti CD 20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a non-myeloablative dose regimen of chimeric rituximab radiolabelled in a hospital. Cancer Bioth Radiopharm 18:513–524

    Google Scholar 

  • van Oers MH (2007) Rituximab maintenance therapy: a step forward in follicular lymphoma. Haematologica 92(6):826–833

    Google Scholar 

  • Visser GW, Klok RP, Gebbinck JW et al (2001) Optimal quality 131I-monoclonal antibodies on high-dose labelling in a large reaction volume and temporarily coating the antibody with IODO-GEN. J Nucl Med 42:509

    CAS  PubMed  Google Scholar 

  • Vose J, Bierman P, Enke C et al (2005) Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J Clin Oncol 23:461–467

    Article  CAS  PubMed  Google Scholar 

  • Zhao WL, Wang L, Liu YH et al (2007) Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin’s B-lymphoma cells apoptosis. Exp Hematol 35(12):1801–1811

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine and Pharmacology, Department of Nuclear Medicine, The University of Western Australia, Fremantle hospital, Alma street, Fremantle, WA 6160, Australia

    J. Harvey Turner

Authors
  1. J. Harvey Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Harvey Turner .

Editor information

Editors and Affiliations

  1. THERANOSTICS Center for Molecular, Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Bad Berka, Germany

    Richard P. Baum

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Harvey Turner, J. (2012). Treatment of Lymphoma with 131I-Chimeric Monoclonal Antibodies. In: Baum, R. (eds) Therapeutic Nuclear Medicine. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2012_734

Download citation

  • DOI: https://doi.org/10.1007/174_2012_734

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-36718-5

  • Online ISBN: 978-3-540-36719-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation